Alert
Upgrade to PRO+
PRO+ subscribers get unlimited access to EMARKETER charts and data. Utilize our vast library of charts to validate strategic ideas and establish thought leadership via internal and external presentations.
Upgrade to PRO+
PRO+ subscribers get unlimited access to EMARKETER charts and data. Utilize our vast library of charts to validate strategic ideas and establish thought leadership via internal and external presentations.
Request successfully sent
Thank you. A member of our team will reach out shortly.
If you need immediate assistance, email us at sales@emarketer.com
February 14, 2022
Top 3 Reasons to Prescribe Prescription Digital Therapeutics (PDTs) According to US Physicians*, Oct 2021 (% of respondents)
Note
Data was provided to Insider Intelligence by Cowen & Company.Methodology
Data is from the February 2022 Cowen & Company "Physician Survey on Prescription Digital Therapeutics." 200 US physicians were surveyed during September-October, 2021, spanning across four indications: type 2 diabetes, pediatric attention-deficit/hyperactivity disorder (ADHD), substance use and opioid disorder, and chronic insomnia. The five products around which the survey centered are BT-001 (Better Therapeutics), EndeavorRx (Akili Interactive), reSET and reSET-O (Pear Therapeutics), and Somryst (Pear Therapeutics). This list is not exhaustive of all PDTs, either approved or in development. Cowen & Company, LLC and or its affiliates make a market in the stock of Better Therapeutics and Pear Therapeutics securities.Featured In
AstraZeneca pours millions into a digital health startup, but it lags behind pharma peers in digital healthThe Rise of Digital TherapeuticsPfizer, SideKick health expand digital therapeutic partnershipHappify Health’s rebrand signals there are too many health apps out thereAdvocates of digital therapeutics push for their own evidence standard Bayer partners with Mahana Therapeutics on digital precision healthSources
Chart Title
Top 3 Reasons to Prescribe Prescription Digital Therapeutics (PDTs) According to US Physicians*, Oct 2021 (% of respondents)Publication Date
February 14, 2022